BREYANZI has significant market potential due to its innovative approach as a CD19-directed chimeric antigen receptor (CAR) T-cell therapy. The growing prevalence of hematologic malignancies ...
DelveInsight's 'BREYANZI Market Size, Forecast, and Market Insight Report' highlights the details around BREYANZI, a CD19-directed CAR ...
Rigrodsky Law, P.A., with offices in Delaware and New York, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in securities ...
Bristol Myers Squibb will acquire 2seventy bio for about $286 million in cash, sending the cancer cell therapy maker's shares ...
4don MSN
We recently published a list of Jim Cramer’s Latest Portfolio: Top 10 Stocks to Watch. In this article, we are going to take a look at where Bristol-Myers Squibb. Co (NYSE:BMY) stands against other ...
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Edgewise Therapeutics (EWTX – Research Report) and Walgreens ...
Researchers from the University of Chicago Medicine Comprehensive Cancer Center demonstrated the potential of a novel treatment approach including immunotherapy to treat advanced human papillomavirus ...
ReviveMed's AI platform analyzes metabolite data, revealing insights into diseases and streamlining drug development for ...
DelveInsight's "XPOVIO Market Size, Forecast, and Market Insight Report" highlights the details around XPOVIO, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback